SRPT Company Profile and Key Details

Q: Who are the executives of SRPT?

Mr. Ian Michael EstepanExecutive Vice President & Chief Financial OfficerMs. Alison NasisiExecutive Vice President & Chief People OfficerMr. Douglas S. Ingram Esq.Pres, Chief Executive Officer & DirectorBilal ArifSenior Vice President of Strategy and Operations & Chief Technical Operations OfficerMary JenkinsSenior Mang. of Investor RelationsMr. Dallan MurrayExecutive Vice President & Chief Customer OfficerDr. Diane L. BerrySenior Vice President of Global Health Policy and Gov. & Patient AffairsMr. William F. CiambroneExecutive Vice President of Technical OperationsMr. Ryan E. BrownSenior Vice President, Gen. Counsel & Corporation Sec.Mr. Will TiltonSenior Vice President, Head of Strategy & Chief of StaffMr. Ryan E. Brown J.D.Executive Vice President, Gen. Counsel & Corporation Sec.Mr. Joseph BraticaController & Vice PresidentMr. Bilal ArifExecutive Vice President & Chief Technical Operations OfficerDr. Diane L. Berry Ph.D.Executive Vice President and Chief of Global Policy & Advocacy OfficerDr. Louise R. Rodino-Klapac Ph.D.Executive Vice President, Chief Scientific Officer and Head of R&D

NASDAQ : SRPT

Sarepta Therapeutics

$21.37

0.33+1.57%

Open: 3:57 PM

61.3

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Sarepta Therapeutics, Inc. (SRPT) stock surged +1.57%, trading at $21.37 on NASDAQ, up from the previous close of $21.04. The stock opened at $20.98, fluctuating between $20.90 and $21.88 in the recent session.

Stock Snapshot

21.04

Prev. Close

2.24B

Market Cap

20.9

Day Low

-7.55

P/E Ratio

-2.83

EPS (TTM)

-6.28

Cash Flow per Share

20.98

Open

104.79M

Number of Shares

21.875

Day High

89.7%

Free Float in %

9.18

Book Value

1.75M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	20.53	21.22	20.10	21.04	1.74M
Jan 16, 2026	21.25	21.51	20.81	21.13	2.26M
Jan 15, 2026	22.68	22.70	21.01	21.31	3.14M
Jan 14, 2026	21.56	23.00	20.94	22.80	3.12M
Jan 13, 2026	21.25	21.96	21.14	21.46	3.15M
Jan 12, 2026	23.93	24.05	20.21	21.14	6.57M
Jan 09, 2026	23.67	23.89	23.05	23.83	2.03M
Jan 08, 2026	23.23	24.12	22.90	23.15	3.06M
Jan 07, 2026	22.50	24.10	22.17	23.46	3.28M
Jan 06, 2026	21.14	22.55	21.14	22.35	3.78M
Jan 05, 2026	21.40	21.97	20.86	21.07	2.97M
Jan 02, 2026	21.92	22.00	21.20	21.31	1.89M
Dec 31, 2025	21.45	21.77	21.33	21.52	1.83M
Dec 30, 2025	21.79	21.91	21.40	21.49	2.07M
Dec 29, 2025	21.81	21.96	21.36	21.82	2.59M
Dec 26, 2025	22.36	22.41	21.86	22.12	1.39M
Dec 24, 2025	21.96	22.46	21.82	22.32	1.25M
Dec 23, 2025	21.19	22.52	21.10	22.00	2.78M
Dec 22, 2025	20.87	21.53	20.86	21.23	2.28M
Dec 19, 2025	20.33	21.48	20.33	21.04	6.02M

Contact Details

Cambridge, MA 02142

United States

https://www.sarepta.com 617 274 4000

About Company

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed at $21.38 USD, gaining $0.34 (1.59%) from the previous close of $21.04. The stock is currently mid-range between its 52-week high and low $10.42 and $120.05. With a market capitalization of about $2.24 billion, Sarepta Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 4.12 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Sarepta Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Douglas S. Ingram, the company employs approximately 1,372 people and listed since June 04, 1997. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

Technical Performance

SRPT has shown mixed momentum, losing -0.47% over the past week and -6.53% over the past quarter, though year-to-date performance is down -2.23%. Short-term trend indicators are mixed aligned (SMA20 -3.84%, SMA50 2.06%, SMA200 -20.22%). The stock’s 14-day RSI is 46.8 (neutral), while the ATR of 1.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.47% below its high and over 102.02% above its low. Average 10-day trading volume of 3.33 million shares is below the 3-month average of 3.98 million, indicating normal recent market interest.

Valuation Metrics

Sarepta Therapeutics, Inc. trades at a P/E ratio of -7.72, slightly below the S&P 500 average, with a price-to-sales ratio of 0.91 and a price-to-book ratio of 1.59 suggesting the stock is closer to book value. The P/FCF stands at -5.63, also above market averages.

Dividend & Fair Value

Sarepta Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $137.69. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 2.11% annually over the next five years. The latest quarter delivered EPS of -$1.83. The next quarter is forecast at -$1.17. Next year's EPS is expected at $146.09. Analyst sentiment is neutral. Analyst rating data shows there are 21 Strong Buy ratings, 10 Buy ratings, 36 Hold ratings, 10 Sell rating and 4 Strong Sell ratings. Price targets range from $202.00 to $5.00. The high target offers 860.08% upside. The low target suggests -76.24% downside. The mean target is $48.91. This offers 132.46% upside. Sarepta Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by -18360.4%. The prior quarter beat by 81.98%. Over the last six quarters, Apple has recorded several small beats. These include 1300.0% in August 07, 2024.

Shareholding & Insider Activity

Sarepta Therapeutics, Inc. has 104.67 million shares outstanding. The public float is 88.27 million shares, elevated short interest at 21.90% of float. This equals 18.24 million shares. The short ratio is 0.87 days. Institutional investors hold 89.59% of the float. Insiders own 5.17%. INGRAM DOUGLAS S holds 375.16 thousand shares, Chambers Michael Andrew has 260.10 thousand shares and Estepan Ian Michael has 193.30 thousand shares. Over the past six months, insider transactions show net selling. They sold 13.19 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Sarepta Therapeutics generated $1.24B in revenue, or $13.46 per share. Gross margin was 87.91%, operating margin -21.54%, and net profit margin -43.11%. Returns are negative, with ROA at -16.42% and ROE at -62.37%.
On valuation metrics, Sarepta Therapeutics trades at a P/E of -7.72, P/S of 0.91 and P/B of 1.59. The current ratio is 2.95 and quick ratio is 1.79. Operationally, the company’s inventory turnover is 0.53 and cash conversion cycle is 707.95 days. Debt-to-equity is 0.95, supported by a cash flow-to-debt ratio of -0.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Sarepta Therapeutics posted revenue of $1.24B, down slightly from $933.01M in the prior quarter. Gross profit was $1.09B (margin 87.91%). Operating income was - $267.82M (margin -21.5%). Net income was- $535.98M (EPS - $5.80).
The company ended the quarter with $1.68B in cash and short-term investments, a total debt of $1.40B, and net debt of $968.38M. Total assets were $3.26B, with equity of $859.34M. Financials further reflected weakness, with operating cash flow of - $500.99M, free cash flow of - $588.34M, and capital expenditures of - $87.35M.

Price Forecast & Outlook

Our AI price prediction model suggests that Sarepta Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.0%, with price expected at $21.25 by February 03, 2026, within a range of $20.28 to $22.17 3-Month Outlook: Projected fall of -60.79%, reaching $8.25 by April 16, 2026, with a range of $5.87 to $10.06. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by January 15, 2027, within a range of $0.00 to $0.72.

Key Takeaways

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares are flat -2.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Sarepta Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.72. Analyst sentiment is cautious, with the majority of ratings in Sell territory and a mean price target of $106.28, suggesting 405.13% upside. Our AI forecast model points to short-term strength (1.0% over two weeks), a medium-term fall (-60.79% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Sarepta Therapeutics, Inc. (SRPT) stock price?

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock price is $21.37 in the last trading session. During the trading session, SRPT stock reached the peak price of $21.88 while $20.90 was the lowest point it dropped to. The percentage change in SRPT stock occurred in the recent session was 1.57% while the dollar amount for the price change in SRPT stock was $0.33.

SRPT's industry and sector of operation?

The NASDAQ listed SRPT is part of Biotechnology industry that operates in the broader Healthcare sector. Sarepta Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SRPT?

Mr. Ian Michael Estepan
Executive Vice President & Chief Financial Officer
Ms. Alison Nasisi
Executive Vice President & Chief People Officer
Mr. Douglas S. Ingram Esq.
Pres, Chief Executive Officer & Director
Bilal Arif
Senior Vice President of Strategy and Operations & Chief Technical Operations Officer
Mary Jenkins
Senior Mang. of Investor Relations
Mr. Dallan Murray
Executive Vice President & Chief Customer Officer
Dr. Diane L. Berry
Senior Vice President of Global Health Policy and Gov. & Patient Affairs
Mr. William F. Ciambrone
Executive Vice President of Technical Operations
Mr. Ryan E. Brown
Senior Vice President, Gen. Counsel & Corporation Sec.
Mr. Will Tilton
Senior Vice President, Head of Strategy & Chief of Staff
Mr. Ryan E. Brown J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. Joseph Bratica
Controller & Vice President
Mr. Bilal Arif
Executive Vice President & Chief Technical Operations Officer
Dr. Diane L. Berry Ph.D.
Executive Vice President and Chief of Global Policy & Advocacy Officer
Dr. Louise R. Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer and Head of R&D

How SRPT did perform over past 52-week?

SRPT's closing price is 101.92% higher than its 52-week low of $10.42 where as its distance from 52-week high of $120.05 is -82.47%.

How many employees does SRPT have?

Number of SRPT employees currently stands at 1,372.

Link for SRPT official website?

Official Website of SRPT is: https://www.sarepta.com

How do I contact SRPT?

SRPT could be contacted at phone 617 274 4000 and can also be accessed through its website. SRPT operates from 215 First Street, Cambridge, MA 02142, United States.

How many shares of SRPT are traded daily?

SRPT stock volume for the day was 1.75M shares. The average number of SRPT shares traded daily for last 3 months was 4.12M.

What is the market cap of SRPT currently?

The market value of SRPT currently stands at $2.24B with its latest stock price at $21.37 and 104.79M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1372
Beta	0.48
Sales or Revenue	$1.24B
5Y Sales Change%	1.961%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SRPT Company Profile and Key Details

Sarepta Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Earnings & Analyst Outlook

Valuation Metrics